重症监护病房肝病患者的血栓预防与出血控制

邢文立; 李谦

doi:10.3969/j.issn.1001-5256.2018.10.039

重症监护病房肝病患者的血栓预防与出血控制

DOI: 10.3969/j.issn.1001-5256.2018.10.039

邢文立,
李谦

天津市第二人民医院ICU天津市肝病医学研究所

详细信息

中图分类号: R575
计量
- 文章访问数: 1766
- HTML全文浏览量: 44
- PDF下载量: 375
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-17
- 出版日期: 2018-10-20

Thromboprophylaxis and bleeding control in patients with liver disease in the intensive care unit

Xing WenLi,
Li Qian

Intensive Care Unit, Tianjin Second People's Hospital & Tianjin Institute of Hepatology

摘要

摘要: 肝脏涉及多种与凝血相关的蛋白合成,常常伴有复杂的凝血系统异常。实验室及临床证据提示肝病患者会达到一个凝血再平衡的状态,但是这种平衡状态相对脆弱,所以临床上出血及血栓形成事件常有发生。急、慢性肝病患者都可能因为出血或血栓形成等各种严重的并发症而进入重症监护病房。胃肠道出血、全身或局部血栓形成和体外循环中发生的凝血事件等是重症监护病房中肝病患者常见的并发症。给予肝病患者个体化的预防血栓形成的治疗,并给予限制性的输血策略(等待观察策略)是合理的。
- 肝疾病 /
- 止血障碍 /
- 输血 /
- 血栓形成 /
- 综述
Abstract: Liver diseases are associated with complex abnormalities in the coagulation system as the liver is involved in the synthesis of various coagulation-related proteins. Laboratory and clinical evidence suggests that patients with liver disease may achieve a state of rebalanced hemostasis, but such balance is relatively unstable, and thus bleeding and thrombosis events are observed in clinical practice. Patients with acute or chronic liver diseases might be admitted to the intensive care unit ( ICU) due to serious complications such as bleeding and thrombosis. Gastrointestinal bleeding, systemic or local thrombosis, and coagulation events in extracorporeal circulation are common complications observed in patients with liver disease in the ICU. An individualized management plan of thromboprophylaxis and a wait-and-see policy for limited blood transfusion are reasonable for patients with liver disease.
- liver diseases /
- hemostatic disorders /
- blood transfusion /
- thrombosis /
- review

HTML全文

参考文献(46)

[1]LISMAN T, LEEBEEK FW, de GROOT PG.Haemostatic abnormalities in patients with liver disease[J].J Hepatol, 2002, 37 (2) :280-287.

[2]CHEN J, CONG YL.Changes of hemostatic indexes in chronic hepatitis B, liver cirrhosis and liver failure[J].Chin J Lab Med, 2015, 38 (2) :128-130. (in Chinese) 陈静, 丛玉隆.止凝血相关指标在慢性乙型肝炎与肝硬化及肝衰竭中的变化趋势[J].中华检验医学杂志, 2015, 38 (2) :128-130.

[3]LISMAN T, BERNAL W.Management of hemostatic disorders in patients with advanced liver disease admitted to an intensive care unit[J].Transfus Med Rev, 2017, 31 (4) :245-251.

[4]TRIPODI A, MANNUCCI PM.The coagulopathy of chronic liver disease[J].N Engl J Med, 2011, 365 (2) :147-156.

[5]LI JT, ZHANG ML.Clinical analysis of 2 cases of liver cirrhosis complicated with venous thrombosis of lower extremity[J].Chin JMed Offic, 2018, 46 (3) :376. (in Chinese) 李军婷, 张美琳.肝硬化并下肢静脉血栓形成2例临床分析[J].临床军医杂志, 2018, 46 (3) :376.

[6]AGARWAL B, GATT A, RIDDELL A, et al.Hemostasis in patients with acute kidney injury secondary to acute liver failure[J].Kidney Int, 2013, 84 (1) :158-163.

[7]HUGENHOLTZ GC, MACRAE F, ADELMEIJER J, et al.Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen[J].JThromb Haemost, 2016, 14 (5) :1054-1066.

[8]LISMAN T, BONGERS TN, ADELMEIJER J, et al.Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity[J].Hepatology, 2006, 44 (1) :53-61.

[9]HUGENHOLTZ GC, ADELMEIJER J, MEIJERS JC, et al.An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure:implications for hemostasis and clinical outcome[J].Hepatology, 2013, 58 (2) :752-761.

[10]LISMAN T, LEEBEEK FW, MOSNIER LO, et al.Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis[J].Gastroenterology, 2001, 121 (1) :131-139.

[11]LISMAN T, PORTE RJ.Value of preoperative hemostasis testing in patients with liver disease for perioperative hemostatic management[J].Anesthesiology, 2017, 126 (2) :338-344.

[12]NAPOLITANO G, IACOBELLIS A, MERLA A, et al.Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia[J].Eur J Intern Med, 2017, 38:79-82.

[13]SEEFF LB, EVERSON GT, MORGAN TR, et al.Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial[J].Clin Gastroenterol Hepatol, 2010, 8 (10) :877-883.

[14]de GOTTARDI A, THEVENOT T, SPAHR L, et al.Risk of complications after abdominal paracentesis in cirrhotic patients:a prospective study[J].Clin Gastroenterol Hepatol, 2009, 7 (8) :906-909.

[15]PERDIGAO JP, de ALMEIDA PC, ROCHA TD, et al.Postoperative bleeding after dental extraction in liver pretransplant patients[J].J Oral Maxillofac Surg, 2012, 70 (3) :e177-184.

[16]MASSICOTTE L, THIBEAULT L, ROY A.Classical notions of coagulation revisited in relation with blood losses, transfusion rate for700 consecutive liver transplantations[J].Semin Thromb Hemost, 2015, 41 (5) :538-546.

[17]MASSICOTTE L, BEAULIEU D, THIBEAULT L, et al.Coagulation defects do not predict blood product requirements during liver transplantation[J].Transplantation, 2008, 85 (7) :956-962.

[18]LEVI M, van der POLL T.Coagulation and sepsis[J].Thromb Res, 2017, 149:38-44.

[19]SENZOLO M, CHOLONGITAS E, THALHEIMER U, et al.Heparin-like effect in liver disease and liver transplantation[J].Clin Liver Dis, 2009, 13 (1) :43-53.

[20]AMBROSINO P, TARANTINO L, Di MINNO G, et al.The risk of venous thromboembolism in patients with cirrhosis.A systematic review and meta-analysis[J].Thromb Haemost, 2017, 117 (1) :139-148.

[21]VALLA D.Splanchnic vein thrombosis[J].Semin Thromb Hemost, 2015, 41 (5) :494-502.

[22]TANG W, WANG Y, ZHAO XY, et al.Impact of portal vein thrombosis on prognosis of patients with liver cirrhosis[J].J Clin Heptal, 2017, 33 (3) :466-471. (in Chinese) 汤雯, 王宇, 赵新颜, 等.门静脉血栓对肝硬化患者预后的影响[J].临床肝胆病杂志, 2017, 33 (3) :466-471.

[23]COOK D, CROWTHER M, MEADE M, et al.Deep venous thrombosis in medical-surgical critically ill patients:prevalence, incidence, and risk factors[J].Crit Care Med, 2005, 33 (7) :1565-1571.

[24]HUGENHOLTZ GC, NORTHUP PG, PORTE RJ, et al.Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?[J].Blood Rev, 2015, 29 (2) :127-136.

[25]MOOREHEAD KJ, JEFFRES MN, MUELLER SW.A retrospective cohort analysis of pharmacologic VTE prophylaxis and padua prediction score in hospitalized patients with chronic liver disease[J].JPharm Pract, 2017, 30 (1) :58-63.

[26]POTZE W, ARSHAD F, ADELMEIJER J, et al.Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis[J].PLo S One, 2014, 9 (2) :e88390.

[27]HANIFY JM, DUPREE LH, JOHNSON DW, et al.Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis[J].J Crit Care, 2017, 37:206-210.

[28] KEARON C, AKL EA, COMEROTA AJ, et al.Antithrombotic therapy for VTE disease:Antithrombotic therapy and prevention of thrombosis, 9th ed:american college of chest physicians evidence-based clinical practice guidelines[J].Chest, 2012, 141 (Suppl2) :e419S-e496S.

[29]CHEN DF, XIONG J.Advances in mechanisms and treatment of portal vein thrombosis in patients with liver cirrhosis[J].J Clin Hepatol, 2017, 33 (3) :451-453. (in Chinese) 陈东风, 熊吉.肝硬化门静脉血栓形成的机制与治疗进展[J].临床肝胆病杂志, 2017, 33 (3) :451-453.

[30]NORTHUP PG, SUNDARAM V, FALLON MB, et al.Hypercoagulation and thrombophilia in liver disease[J].J Thromb Haemost, 2008, 6 (1) :2-9.

[31]DROLZ A, HORVATITS T, ROEDL K, et al.Coagulation parameters and major bleeding in critically ill patients with cirrhosis[J].Hepatology, 2016, 64 (2) :556-568.

[32]ALKOZAI EM, LISMAN T, PORTE RJ.Bleeding in liver surgery:prevention and treatment[J].Clin Liver Dis, 2009, 13 (1) :145-154.

[33]SPIESS BD.Transfusion of blood products affects outcome in cardiac surgery[J].Semin Cardiothorac Vasc Anesth, 2004, 8 (4) :267-281.

[34]de BOER MT, CHRISTENSEN MC, ASMUSSEN M, et al.The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation[J].Anesth Analg, 2008, 106 (1) :32-44.

[35]TOY P, GAJIC O, BACCHETTI P, et al.Transfusion-related acute lung injury:incidence and risk factors[J].Blood, 2012, 119 (7) :1757-1767.

[36]WEEDER PD, PORTE RJ, LISMAN T.Hemostasis in liver disease:implications of new concepts for perioperative management[J].Transfus Med Rev, 2014, 28 (3) :107-113.

[37]NORTHUP PG, CALDWELL SH.Coagulation in liver disease:a guide for the clinician[J].Clin Gastroenterol Hepatol, 2013, 11 (9) :1064-1074.

[38]MULLER MC, ARBOUS MS, SPOELSTRA-DE MAN AM, et al.Transfusion of fresh-frozen plasma in critically ill patients with a coagulopathy before invasive procedures:a randomized clinical trial (CME) [J].Transfusion, 2015, 55 (1) :26-35;quiz 25.

[39]JIA Q, BROWN MJ, CLIFFORD L, et al.Prophylactic plasma transfusion for surgical patients with abnormal preoperative coagulation tests:a single-institution propensity-adjusted cohort study[J].Lancet Haematol, 2016, 3 (3) :e139-148.

[40]STANWORTH SJ, WALSH TS, PRESCOTT RJ, et al.A national study of plasma use in critical care:Clinical indications, dose and effect on prothrombin time[J].Crit Care, 2011, 15 (2) :R108.

[41]LISMAN T, STRAVITZ RT.Rebalanced hemostasis in patients with acute liver failure[J].Semin Thromb Hemost, 2015, 41 (5) :468-473.

[42]MALLETT SV.Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation[J].Semin Thromb Hemost, 2015, 41 (5) :527-537.

[43]KIRCHNER C, DIRKMANN D, TRECKMANN JW, et al.Coagulation management with factor concentrates in liver transplantation:a single-center experience[J].Transfusion, 2014, 54 (10 Pt 2) :2760-2768.

[44]ROBERTS LN, BERNAL W.Management of bleeding and thrombosis in critically ill patients with liver disease[J].Semin Thromb Hemost, 2015, 41 (5) :520-526.

[45]MEYER AV, GREEN M, PAUTLER HM, et al.Impact of vitamin K administration on INR changes and bleeding events among patients with cirrhosis[J].Ann Pharmacother, 2016, 50 (2) :113-117.

[46]SAJA MF, ABDO AA, SANAI FM, et al.The coagulopathy of liver disease:does vitamin K help?[J].Blood Coagul Fibrinolysis, 2013, 24 (1) :10-17.

施引文献

资源附件(0)

访问统计